EU and US could reach trade deal this weekend - Reuters
James D. Clark, the Senior Vice President and Chief Accounting Officer at CVS Health Corp (NYSE:CVS), recently sold shares in the company. According to a Form 4 filing with the Securities and Exchange Commission, Clark sold a total of 7,513 shares of common stock on March 5, 2025, at a price of $66.35 per share, amounting to $498,487. The transaction comes as CVS, currently valued at $83.77 billion, shows strong momentum with a 47.2% return year-to-date. InvestingPro analysis indicates the stock is trading below its Fair Value, with 13 analysts recently revising earnings estimates upward.
On the same day, Clark also acquired 7,513 shares through the exercise of stock options at a price of $62.21 per share. After these transactions, Clark holds 8,394 shares of CVS Health stock directly. The stock options exercised were part of a grant that became exercisable in four equal annual installments, starting on April 1, 2019. The company has maintained dividend payments for 55 consecutive years, with a current yield of 4.08%. Discover more insights about CVS’s financial health and growth potential with a comprehensive Pro Research Report, available exclusively on InvestingPro.
In other recent news, CVS Health has been involved in several significant developments. CVS Health’s fourth-quarter earnings for 2024 exceeded expectations, with an adjusted earnings per share of $1.19, 29% higher than consensus estimates. This performance led Bernstein to raise CVS Health’s stock price target to $71, citing the strong earnings potential of Aetna, a part of CVS Health. Additionally, CVS Health has introduced a new 3-in-1 test for Influenza A, Influenza B, and COVID-19 at 1,600 locations, enhancing its flu testing and treatment capabilities. The company also announced the availability of flu and COVID-19 vaccines at CVS Pharmacy and MinuteClinic locations.
In a strategic move, CVS Health sold its Medicare Shared Savings Program business to Wellvana, gaining a minority stake in the company. This acquisition allows Wellvana to expand its network across 40 states and serve approximately 1 million Medicare patients. Meanwhile, a DOJ investigation into UnitedHealth Group (NYSE:UNH)’s Medicare billing practices has raised concerns across the healthcare sector, including CVS Health, although no direct accusations have been made against CVS. Lastly, Karen S. Lynch, former CEO of CVS Health, has joined the board of Thermo Fisher Scientific (NYSE:TMO), bringing her extensive healthcare experience to the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.